^*Retinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, University of California Los Angeles, Los Angeles, CA

^†Department of Ophthalmology, Ain Shams University Hospitals, Cairo, Egypt

^‡Department of Ophthalmology, Université Paris Cité, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France

^§Doheny Eye Institute, University of California Los Angeles, Los Angeles, CA

E. Bousquet has been a consultant for Bayer and Allergan and received personal fees from Novartis. S.R. Sadda receives personal fees from Amgen, Allergan/Abbvie, Apellis, Iveric, Oxurion, Roche/Genentech, Novartis, Bayer, Regeneron, Jannsen, Nanoscope, Biogen, Boerhinger Ingelheim, Centervue, Heidelberg, Nidek, Optos, and Notal; grants from Carl Zeiss Meditec; nonfinancial support from Topcon, Carl Zeiss Meditec, Centervue, Heidelberg, Nidek, and Optos. D. Sarraf receives grants, personal fees from Amgen, personal fees from Bayer, grants from Boehringer, grants from Genentech, non-financial support from Heidelberg, personal fees from Novartis, personal fees, non-financial support from Optovue/Visionix, grants from Regeneron, nonfinancial support from Topcon, personal fees from Iveric Bio. The remaining authors have no financial disclosures.